Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012–2018

• Published in: Cancer causes & control Vol. 34; no. 3; pp. 205 - 212
• Main Authors: Kao, Szu-Yu Zoe, Ekwueme, Donatus U., Holman, Dawn M., Rim, Sun Hee, Thomas, Cheryll C., Saraiya, Mona
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2023; Springer Nature B.V
• Subjects: Adult; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer therapies; Cost of Illness; Costs; Epidemiology; Expenditures; Financial Stress; Health Care Costs; Health Expenditures; Hematology; Humans; Melanoma; Melanoma - epidemiology; Melanoma - therapy; Oncology; Original Paper; Public Health; Skin cancer; Skin Neoplasms - epidemiology; Skin Neoplasms - therapy; Surveys; United States - epidemiology; United States; United States > US; Medical Expenditure Panel Survey; Skin cancer treatment; Treatment costs; Treated prevalence
• ISSN: 0957-5243; 1573-7225; 1573-7225
• DOI: 10.1007/s10552-022-01644-0

Purpose We report the prevalence and economic cost of skin cancer treatment compared to other cancers overall in the USA from 2012 to 2018. Methods Using the Medical Expenditure Panel Survey full-year consolidated data files and associated medical conditions and medical events files, we estimate the prevalence, total costs, and per-person costs of treatment for melanoma and non-melanoma skin cancer among adults aged ≥ 18 years in the USA. To understand the changes in treatment prevalence and treatment costs of skin cancer in the context of overall cancer treatment, we also estimate the prevalence, total costs, and per-person costs of treatment for non-skin cancer among US adults. Results During 2012–15 and 2016–18, the average annual number of adults treated for any skin cancer was 5.8 (95% CI: 5.2, 6.4) and 6.1 (95% CI: 5.6, 6.6) million, respectively, while the average annual number of adults treated for non-skin cancers rose from 10.8 (95% CI: 10.0, 11.5) to 11.9 (95% CI: 11.2, 12.6) million, respectively. The overall estimated annual costs rose from $8.0 (in 2012–2015) to $8.9 billion (in 2016–18) for skin cancer treatment and $70.2 to $79.4 billion respectively for non-skin cancer treatment. Conclusion The prevalence and economic cost of skin cancer treatment modestly increased in recent years. Given the substantial cost of skin cancer treatment, continued public health attention to implementing evidence-based sun-safety interventions to reduce skin cancer risk may help prevent skin cancer and the associated treatment costs.